Project Grant R21AI202577
Award Date 8/21/26
Completion Date 7/31/28
Dollars Obligated $231K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lauderdale, MN 55108, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $806,000 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of secreted bacterial effectors in Group B Streptococcus (GBS) intestinal colonization and systemic neonatal infection. The research examines how GBS type VII secretion system effectors promote intestinal dysbiosis, impair immune responses, disrupt intestinal barrier function, and...
- The National Institute of Allergy and Infectious Diseases awarded New York University School of Medicine $206,496 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genome-wide fitness analysis of Group B Streptococcus in intestinal colonization. The research uses transposon insertion sequencing to identify bacterial genes essential for gastrointestinal colonization in a murine model of postnatal Group B Streptococcus acquisition. The work...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $423,500 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will generate and validate a series of TAM receptor tyrosine kinase (Tyro3, Axl, and Merkt) mutant mice designed to disentangle specific effector functions—phagocytosis of dead cells and anti-inflammatory signaling—rather than produce complete knockouts. By substituting...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $110,228 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural and functional mechanisms of antibiotic substrate translocation in bacterial resistance-nodulation-division (RND) family efflux pumps. The research addresses the challenge of intrinsic antibiotic resistance in Pseudomonas aeruginosa, which encodes twelve RND efflux pumps, at least four of...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $529,512 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the mechanism of intoxication of the Clostridioides difficile transferase. The research uses cryogenic electron microscopy, biochemical and biophysical assays, and cellular biology to address two key questions: how toxin assembly is regulated and triggered, and what...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Methodist Hospital Research Institute a Project Grant of $444,125 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2027. This research project will characterize a previously unknown intercellular signaling pathway in Group B Streptococcus (GBS) and determine its contribution to bacterial pathogenesis. Specifically,...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $182,391 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell-painting strategies that enhance vaccine efficacy and immune activation through B cell targeting. The research develops amphiphile-protein conjugate vaccines that hitchhike on albumin to enter lymphoid tissues and activate germinal center responses, with the ability to...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Berkeley $156,104 under the Allergy and Infectious Diseases Research program on March 9, 2026, to investigate how gut bacteria mitigate Shigella infection through bacterial culturing and gnotobiotic mouse models. The research examines the effects of various gut bacteria on Shigella growth and virulence through growth curve assays and fluorescent reporter plasmid techniques, with focus on how commensal...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $380,000 on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bespoke micellar nanoparticles for in vivo delivery of digital base editor treatments for primary immunodeficiency disease. The recipient will synthesize a novel uniform library of amphiphilic polymers and optimize micellar nanoparticles for binary base editor (guide RNA and...